New Medicines

Annovera (US) Contraception


Annovera (US)
New molecular entity
Not Known

Development and Regulatory status

Dec 19Annovera was originally developed by Antares Pharma and the Population Council. The Population Council conducts research to address critical health and development issues. It conducts research and programs in more than 50 countries. Its New York headquarters supports a global network of offices in Africa, Asia, Latin America, and the Middle East. UK launch seems unlikely [5,6].
Dec 19Annovera is available in the US [4].
Aug 18FDA advise that women aged >35 who smoke should not use Annovera, and the ring carries a boxed warning relating to cigarette smoking and serious cardiovascular events, similar to other hormonal contraceptives. The FDA is requiring postmarket studies on the risk of venous thromboembolism and the effects of tampon use and CYP3A modulating drugs on Annovera’s pharmacokinetics.[2]
Aug 18Approved by FDA. It is expected that Annovera will be fully commercially available in late 2019 or early 2020.[2]
Jan 18Filed for approval with US FDA.[2]


A self-administered vaginal ring composed of ethinyl estradiol + segestrerone acetate (a 4th generation progestin). Each cycle will consist of 21 days of vaginal ring use followed by 7 vaginal ring-free days - can be used for up to 1 year.
The last survey on contraceptive use was done by the Office for National Statistics (ONS) in 2008-9 and at that time showed that 75% of women use some form of contraception [1].

Trial or other data

Aug 18Pooled analysis demonstrated 97.3% of efficacy in preventing pregnancy, from the two PIII trials, which were conducted in 2,111 females ≤35 years of age. the trials met the primary endpoint of Pearl Index of 2.98 per 100 woman-year [6].
Jan 18Two pivotal PIII trials (NCT00455156 and NCT00263341) involving 2270 healthy women aged 18 to 40 years evaluated its safety and efficacy. These showed that ~2-4 women out of 100 may get pregnant during the first year they use Annovera as directed.[2,3]
Jan 18A self-administered silicone rubber vaginal ring composed of ethinyl estradiol + segestrerone acetate (a 4th generation progestin) has been developed by the Population Council (USA) who is developing it with TherapeuticsMD in the USA. The ring is designed to last for 1 year before being replaced, allowing long term delivery of the drugs. It is washed and stored in a compact case for the seven days it´s not in use during a four-week menstrual cycle. It does not require refrigeration and can withstand storage up to 86°F (30°C).[2,3]